{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"45.9","value":"0"},{"groupId":"OG001","lowerLimit":"0.3","upperLimit":"48.2","value":"11.1"},{"groupId":"OG002","lowerLimit":"0.4","upperLimit":"64.1","value":"16.7"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"33.6","value":"0"},{"groupId":"OG004","lowerLimit":"20.8","upperLimit":"53.8","value":"36.1"},{"groupId":"OG005","lowerLimit":"40.8","upperLimit":"84.6","value":"65.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"20"}],"units":"Participants"}],"description":"Overall response rate is defined as the percentage of participants with documented best overall response of Partial Response (PR) or better (PR, Very good partial response \\[VGPR\\], Complete response \\[CR\\], or Stringent complete response \\[sCR\\]) per 2011 International Myeloma Working Group (IMWG) criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the dose-escalation cohort received 300 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.","id":"OG000","title":"Phase 1: Venetoclax 300 mg"},{"description":"Participants in the dose-escalation cohort received 600 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.","id":"OG001","title":"Phase 1: Venetoclax 600 mg"},{"description":"Participants in the dose-escalation cohort received 900 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.","id":"OG002","title":"Phase 1: Venetoclax 900 mg"},{"description":"Participants in the dose-escalation cohort received 1200 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.","id":"OG003","title":"Phase 1: Venetoclax 1200 mg"},{"description":"Participants in the safety expansion cohort received 1200 mg of venetoclax daily on Days 1 - 21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.","id":"OG004","title":"Phase 1 Safety Expansion: Venetoclax 1200 mg"},{"description":"Participants with t(11;14) translocation multiple myeloma received daily venetoclax at a dose of 800 mg (no lead-in period) on Days 1- 21 of each cycle concomitant with weekly dexamethasone at a dose of 40 mg (20 mg for those aged ≥ 75 years).","id":"OG005","title":"Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg"}],"paramType":"NUMBER","populationDescription":"All enrolled Phase 1 participants who had active disease at baseline and received venetoclax","reportingStatus":"POSTED","timeFrame":"Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median time on follow-up was 8.1 months","title":"Phase 1: Overall Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}